AVSTERA

Avstera Therapeutics is an oncology-focused biotech company located in the Philadelphia area dedicated to address the large disease burden and significant unmet need of advanced cancer patients. With a focus on foundational tumor biology science, Avstera leverages cutting edge approaches to tackle key immunological challenges seen in the tumor microenvironment. Avstera also is proud to be collaborating with top cancer researchers at both Georgetown University and the University of Pennsylvania... At Avstera, our primary initial focus is to address the significant unmet need of advanced cancer patients who have limited or no treatment options. These include patients who fail to respond to existing therapies, or end up developing resistance to immunotherapy. With our proprietary pipeline of oncology programs, including an ultra-specific immunomodulatory HDAC6i which has been IND cleared by FDA for FIH trials (AVS100), first in class myeloid cell therapy platform (AVS200), and mRNA..

Also known as: Avstera Therapeutics, Avstera Therapeutics Corp

Primary location: Malvern United States